Cell-free DNA As Biomarker in Hodgkin Lymphoma Patients

Introduction Treatment failure or relapse occurs in approximately 10% of early stage Hodgkin lymphoma (HL) patients and 20% of patients who have advanced stage HL. Identifying this group of refractory and relapsed HL patients is crucial in order to plan for effective first line treatment. Considering that genomic aberrations can be readily detected in cfDNA, this method may allow for a non-invasive method of monitoring disease load and serve as a prognostic marker. We aimed to study the genomic profile of HL and correlate these findings to the levels of the circulating biomarker TARC and to other clinical characteristics.